Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Designation Covers Broad Treatment of Epidermolysis Bullosa (EB) Top-Line Phase 3 Data on Track for 3Q17 CRANBURY, N.J., May 31, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics,...
-
CRANBURY, N.J., May 19, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics, Inc. (Nasdaq:FOLD), has completed the analysis plan for the primary endpoints in the blinded ongoing Phase 3 clinical...
-
Mean Six-Minute Walk Distance at Month Six Improved in ERT-Naïve Patients (+52 Meters) and ERT-Switch Patients (+38 Meters) Muscle Function Improved in 9 out of 10 Patients Pulmonary Function...
-
CRANBURY, N.J., May 10, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of rare and orphan diseases, today announced that Chip Baird,...
-
100+ Fabry Disease Patients Now on Reimbursed Galafold (migalastat) in the EU On Target to Reach 300 Patients on Galafold by Year-End 2017 Additional Important Phase 1/2 Pompe Clinical...
-
CRANBURY, N.J., May 02, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of rare and orphan diseases, today announced a conference call and...
-
CRANBURY, N.J. and PARIS, May 02, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of rare and orphan diseases, has commenced the...
-
CRANBURY, N.J., April 06, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of rare and orphan diseases, is supporting several activities...
-
Target Exceeded with More than 160 Patients Enrolled Top-Line Data on Track for 3Q17 CRANBURY, N.J., April 03, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology...
-
CRANBURY, N.J. and MILAN, Italy, March 08, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of rare and orphan diseases, has commenced the...